Updates in Severe Asthma (MOC)
You can earn up to 1.5 AMA PRA Category 1 Credit(s)™. This activity has also been designated by the ABAI for 1.5 MOC Part II Self-Assessment credits. Cost:
$30 $15 for College Members, $45 $25 for non-members.
These presentations will review 1) how basic science research has identified distinct pathophysiological endotypes in severe asthma; 2) the use of biomarkers and other tools to categorize the endotype of a severe asthma patient in the allergy/immunology clinic and indicate how these techniques have the potential to improve the care of patients with severe asthma; and 3) examination of the practical approaches currently qavailable for patients not controlled on Step 4 Therapy and look at the role of biologics that will become available in the future of this patient population.
Release Date: 12/15/2015
Expiration Date: 12/14/2018
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Recognize how basic science research has identified distinct pathophysiological endotypes in severe asthma
• Utilize appropriate biomarkers to categorize the endotype of a severe asthma patient in the allergy/immunology clinic
• Design a management plan that is individualized to a severe asthma patient's particular phenotype and endotype
Gerald B. Lee, MD
Elliot Israel, MD
Stephen P. Peters, MD, PhD
Bradley E. Chipps, MD, FACAAI
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance
- 1.50 MOC